Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Mereo BioPharma Group plc is a biotechnology business based in the US. Mereo BioPharma Group shares (MREO) are listed on the NASDAQ and all prices are listed in US Dollars. Mereo BioPharma Group employs 38 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$2.15|
|52-week range||$1.90 - $4.71|
|50-day moving average||$2.50|
|200-day moving average||$2.94|
|Wall St. target price||$685.01|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.31|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-14)||-4.44%|
|1 month (2021-09-23)||-13.31%|
|3 months (2021-07-23)||-14.00%|
|6 months (2021-04-23)||-37.13%|
|1 year (2020-10-23)||-16.99%|
|2 years (2019-10-23)||-35.63%|
|3 years (2018-10-20)||N/A|
|5 years (2016-10-20)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||-31.43%|
|Return on equity TTM||-1294.27%|
|Market capitalisation||$237.4 million|
TTM: trailing 12 months
There are currently 7.2 million Mereo BioPharma Group shares held short by investors – that's known as Mereo BioPharma Group's "short interest". This figure is 3.9% down from 7.5 million last month.
There are a few different ways that this level of interest in shorting Mereo BioPharma Group shares can be evaluated.
Mereo BioPharma Group's "short interest ratio" (SIR) is the quantity of Mereo BioPharma Group shares currently shorted divided by the average quantity of Mereo BioPharma Group shares traded daily (recently around 785121.17263844). Mereo BioPharma Group's SIR currently stands at 9.21. In other words for every 100,000 Mereo BioPharma Group shares traded daily on the market, roughly 9210 shares are currently held short.
However Mereo BioPharma Group's short interest can also be evaluated against the total number of Mereo BioPharma Group shares, or, against the total number of tradable Mereo BioPharma Group shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Mereo BioPharma Group's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Mereo BioPharma Group shares in existence, roughly 70 shares are currently held short) or 0.1244% of the tradable shares (for every 100,000 tradable Mereo BioPharma Group shares, roughly 124 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Mereo BioPharma Group.
Find out more about how you can short Mereo BioPharma Group stock.
We're not expecting Mereo BioPharma Group to pay a dividend over the next 12 months.
Over the last 12 months, Mereo BioPharma Group's shares have ranged in value from as little as $1.9 up to $4.711. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Mereo BioPharma Group's is 1.5426. This would suggest that Mereo BioPharma Group's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom. .
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.